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Abstract
Objective
To develop a simulation model to identify key bottlenecks in the bladder cancer 
pathway at Royal Cornwall Hospital, and predict the impact of potential changes 
to reduce these delays.
Materials and methods
The diagnosis and treatment of muscle-invasive bladder cancer can suffer 
numerous delays which can significantly affect patient outcomes.  We developed 
a Discrete Event computer simulation model of the flow of patients through the 
bladder cancer pathway at the hospital, using anonymised patient records from 
2014 and 2015.  The changes tested in the model were for patients suspected to 
have muscle-invasive disease on flexible cystoscopy.  Those patients were “fast-
tracked” to receive their Transurethral Resection of Bladder Tumour (TURBT) 
treatment using operating slots kept free for these patients.   A staging CT scan 
was booked in the haematuria clinic. Pathology requests were marked as 48 hour
turn around.   The nurse specialist would then speak to the patient whilst they 
are on the ward following their TURBT to give information about their ongoing 
treatment and provide support.
Results
The model predicted that if the changes were implemented, delays in the system
could be reduced by around five weeks.  The changes were implemented, and 
analysis of three months of the data post-implementation shows that the 
average time in the system has reduced by five weeks.  The environment 
created by the changes in the pathway improved referral to treatment times in 
both muscle invasive and non-muscle invasive groups.
Conclusion
The simulation model proved an invaluable tool for facilitating the 
implementation of changes.  Simple changes to the pathway led to significant 
reductions in delays for bladder cancer patients at Royal Cornwall Hospital.
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A Level of Evidence is not applicable for this study.
Introduction
Bladder cancer is the seventh most common cancer in the UK with about 10,000 
new cases each year 1.  20-25% of these cancers involve the muscle wall of the 
bladder at diagnosis 1, which confers a worse prognosis.  In this group of 
patients, despite treatment, five year survival is only around 50% 2.  The 
standard definitive treatment of non-metastatic muscle invasive bladder cancer 
is radical cystectomy with the use of neoadjuvant cisplatin-based combination 
chemotherapy in appropriate cases.  In patients who are unfit for or unwilling to 
undergo surgery, radiotherapy is a viable alternative option.  Delays to definitive 
treatment are associated with worse outcomes in this aggressive cancer 3-8.
In bladder cancer the “stop the clock” treatment in the 31 and 62 day pathways 
has been the TURBT.  In muscle invasive disease the TURBT can be seen as 
merely a biopsy and not the definitive treatment.  This has meant that, as in the 
case of our institution and region, the cancer pathway targets can be met while 
there is a pronounced delay to definitive treatment in the muscle invasive 
group9. 
The diagnostic pathway for patients with muscle invasive bladder cancer (MIBC) 
is complex and involves multiple investigations, and the potential significant 
delays in this pathway have been demonstrated 9.  Simulation modelling 
methods allow us to identify bottlenecks in real world systems and explore the 
potential impact of changes to the system without the cost and safety risks 
associated with trialling real-world changes without evidence 10.  Such methods 
are increasingly being used to improve the efficiency of patient pathways to 
generate better patient outcomes, and have led to significant increases in stroke
patients receiving life-changing treatment 11, improvements to the organisation 
of networks for neonatal care 12 and a better understanding of the demand for 
urgent and emergency care 13.
In this paper we describe the development and implementation of a Discrete 
Event Simulation model of the bladder cancer pathway at Royal Cornwall 
Hospital (RCHT), Treliske in the UK.  We also present results of an analysis of 
three months of data collected after real-world changes were made, and discuss 
the impact these changes have had for the system and for patients.
Materials and Methods
We developed an in-silico Discrete Event Simulation 14 model of the bladder 
cancer pathway at RCHT Treliske using Simul8 Professional software (SIMUL8; 
SIMUL8 Corporation, Boston, MA; www.Simul8.com).  This type of simulation is 
useful for modelling patient pathways and changes to these pathways because it
allows for a system’s discrete, sequential events and their associated queues to 
be captured.
Model Structure
In our model, patients are referred into the system and first wait to receive a 
renal tract ultrasound and flexible cystoscopy.  Once a tumour has been 
confirmed they are referred for a Transurethral Resection of Bladder Tumour 
(TURBT) to remove or reduce any tumours identified.  The histology from the 
TURBT allows the clinician to identify whether the patient’s bladder cancer is 
muscle-invasive.  Once a diagnosis of muscle-invasion is made, the patient’s 
case is referred for discussion at the local and specialist Multi-Disciplinary Team 
meetings, and a nurse specialist and / or urologist contacts the patient to discuss
the diagnosis and their treatment options.  Once both of these things have 
happened, the case is formally referred to Derriford Hospital in Plymouth for 
consideration of cystectomy and to the local oncologist to discuss neoadjuvant 
chemotherapy.  Figure 1 shows an overview of the processes captured by the 
model.
Figure 1.  Overview of the processes captured by the simulation model.
Some intermediate steps in the real-world process were not explicitly included in 
the model due to lack of data, but are still represented in terms of the delays 
between the activities included in the simulation.
Parameterisation of the Model
We were provided with two years of pseudo-anonymised patient data for bladder
cancer patients referred to RCHT Treliske, comprising 408 records over 2014 and
2015.The average time between referrals in the 2014 and 2015 data was 3.6 
days (standard deviation of 4.9 days).  We used an exponential distribution with 
mean 3.6 days to represent the time between referrals in our model.  The waits 
in the system were represented in the model by using distributions that best fit 
the pattern of the data, and were determined using Stat-Fit software (Stat::Fit; 
Geer Mountain Software Corporation; http://www.geerms.com/) as follows :
 The time between referral and cystoscopy was fitted to a Log Normal 
distribution with mean of 15.5 days and standard deviation of 32.5 days.
 The time between cystoscopy and TURBT was fitted to a Log Normal 
distribution with mean of 43.2 days and standard deviation of 43.9 days.
 The time between TURBT and discussion at the MDT was fitted to a 
Pearson Type VI Distribution with α1 of 30.7, α2 of 4.54, and β of 2.31.
 The time between TURBT and the specialist nurse / urologist contacting 
the patient was fitted to a Pearson Type V Distribution with α of 4 and β of 
75.5.
 Once both the case has been discussed at the MDT and the patient has 
been contacted, the wait for a referral to Derriford Hospital was fitted to a 
Log Normal distribution with mean of 17.7 days and standard deviation of 
19.9 days, and the wait for a referral to the oncologist was fitted to a Log 
Normal distribution with mean of 12.3 days and standard deviation of 20.8
days
In each case, the simulation was run for a simulated period of 10 years.  Each 
scenario was tested by running the simulation five times and taking average 
results over these simulation runs.  This number was calculated by the Simul8 
software as being sufficient to ensure 95% confidence intervals on the output 
mean.
Scenarios Tested
The simulation was first tested with the ‘base case’ scenario – a representation 
of what is happening now in the real world system.  By running this scenario in 
front of oncologists and urologists at the hospital, we were able to visually 
demonstrate in the simulation that there were two key bottlenecks in the system
– patients waiting for their TURBT, and patients waiting for a nurse specialist or 
oncologist to speak to them to discuss their diagnosis and treatment options.
Consequently, the group discussed how they might reduce these bottlenecks and
suggested practical changes that they could make:
 fast-tracking patients with suspected muscle-invasion at their flexible 
cystoscopy to receive their TURBT as quickly as they receive a cystoscopy 
after referral 
 booking staging CT urogram plus thorax in suspected muscle invasive 
disease straight from haematuria clinic 
 fast tracking TURBT pathology specimens (48 hour turn around for 
suspected MIBC)
 asking the nurse specialist to speak to the patient about their diagnosis 
and treatment options whilst they are on the ward for their TURBT 
Therefore, we tested the impact of these changes as our second scenario by 
using the same distribution for both the wait for cystoscopy and the wait for 
TURBT, and by reducing the wait for contact by specialist nurse / urologist to 
zero.
For each scenario run in the model, we recorded the average time spent in the 
system (from initial referral to referral to Derriford Hospital).
Results
Predictions from the Simulation Model
The model predicts that, on average, the time from referral by GP to referral to 
Derriford was 112 days in the base case scenario (95% Confidence Intervals (CI), 
109 days to 114 days).
If the wait for a TURBT was reduced to the same as the wait for cystoscopy after 
referral, and there was no wait to speak to a nurse specialist after the TURBT, 
the model predicts that, on average, the time from referral to referral to 
Derriford would be 75 days (95% CI, 71 days to 78 days).  This represents a 
predicted reduction of 37 days (over five weeks) for the average patient.
Real World Changes from Model Predictions
Given the model predicted a significant reduction to delays in the system if the 
proposed changes were implemented, the consultants at RCHT Treliske were 
keen to implement the changes as quickly as possible.  Within 24 hours from the 
presentation of the results in November 2016, a new protocol was written by the 
Cancer Lead for Urology instructing clinicians to identify any patients suspected 
to have a muscle-invasive tumour on flexible cystoscopy and who would be a 
candidate for cystectomy to have a fast track pre-assessment and TURBT within 
two weeks.  All haematuria clinic flexible cystoscopies at the Royal Cornwall 
Hospital are performed by a consultant urologist or registrar.  The protocol also 
dictates that the nurse specialist should see the patient on the ward during their 
admission.
The trust collected three months of data following the change, consisting of 32 
patient records, including seven who were fast-tracked.  We analysed this data 
to assess whether there had been a reduction in the time from initial referral to 
TURBT and from initial referral to date contacted by the nurse specialist, for both
fast-track patients and across all bladder cancer patients.
Results from the Post-Change Data Analysis
The mean time from initial referral to TURBT has reduced from 57 days (max = 
433 days, min = 8 days) before the changes to 48 days (max = 96 days, min = 
21 days) across all bladder cancer patients, and 32 days (max = 42 days, min = 
21 days) for patients who have been fast-tracked.  This represents an average 
reduction of 9 days across all bladder cancer patients, and 25 days (three and a 
half weeks) for fast-tracked patients.
The mean time from initial referral to date contacted by the nurse specialist has 
reduced from 78 days (max = 408 days, min = 19 days) before the changes to 
67 days (max = 142 days, min = 14 days) across all bladder cancer patients, and
43 days (max = 70 days, min = 14 days) for patients who have been fast-
tracked.  This represents an average reduction of 11 days across all bladder 
cancer patients, and 35 days (five weeks) for fast-tracked patients.
The number of tertiary referrals generated in the post-change cohort was very 
small (1 in the fast-track group and 1 in the non-fast-track group) so it was not 
possible to comment in a meaningful way on the time to either tertiary referral 
or definitive treatment.  We assume that by making relatively large 
improvements in the earlier steps of the pathway the time to definitive 
treatment will improve accordingly.   
Discussion
Our simulation model identified two key bottlenecks in the bladder cancer 
pathway at RCHT Treliske – the wait for a patient to receive a TURBT and the 
wait for a patient to be contacted by the nurse specialist to discuss their 
diagnosis and treatment options.  With the current strain on the NHS waiting lists
for surgery are increasing under pressure.  The process by which all TURBTs are 
listed with the same clinical priority is potentially disadvantaging those with 
more aggressive disease.  Facilitating an early meeting between the CNS and 
patient allows for a relationship to be forged and clinical information given.  It 
makes it easier to have subsequent communication by telephone, allowing the 
patients to be quickly placed into the correct clinic setting while avoiding patient 
confusion and unnecessary outpatient appointments.  
By using the simulation model as both a visualisation tool to clearly show the 
nature and extent of these bottlenecks and facilitate discussion, and as a 
predictive tool to allow “what if” scenarios identified by the collaborators to be 
tested, a hugely convincing case was made to implement specific, simple, 
immediate and cost-neutral changes to the pathway.  Assessment of the data 
three months following the implementation indicates that, as predicted by the 
model, these changes have had a significant impact for bladder cancer patients, 
reducing the time from initial referral to discussion of their diagnosis and 
treatment options by five weeks for patients who have been fast-tracked, and 
over one and half weeks across all bladder cancer patients.  
Multiple studies have shown that in an aggressive cancer like MIBC any delay to 
definitive treatment is likely to affect outcome 3-8.  Therefore, these findings are 
significant and imply that patient’s outcomes are highly likely to have been 
improved by these changes, potentially significantly.  One concern was that, by 
concentrating on the suspected muscle invasive cases, the rest of the new 
bladder cancer patients would be disadvantaged by having their treatment 
delayed.  It is therefore reassuring to observe that there has been a reduction in 
waiting times across all bladder cancer patients and not just those that have 
been fast-tracked.  It is possible that the project’s engagement with a multitude 
of clinicians involved across the bladder cancer pathway across the trust 
(including consultants, surgeons and nurse specialists) helped to increase 
awareness of the delays in the system and instil an increased motivation to 
improve the efficiency of the system.
The preliminary analysis of post-implementation impact of the changes made is 
encouraging, although we should be a little cautious here.  This is only a three 
month analysis, and as such only includes 36 patients, of whom 7 were fast-
tracked.  Further analysis will be necessary after six and / or 12 months to allow 
more patients to be included and give greater power to the analysis.  It will also 
be important to observe whether the impact of the changes have been 
sustained, or whether some momentum has been lost over time.  Nevertheless, 
it is very encouraging to see such a direction and extent of travel in outcomes for
all bladder cancer patients in the months immediately following the 
implementation of these changes.  There is also a further question as to how 
good clinicians are at identifying muscle invasive disease at the initial flexible 
cystoscopy, particularly as a failure to identify a high risk patient may also affect 
their pathway negatively.  Our initial analysis indicates that all seven fast-
tracked patients had clinically significant cancers, and two of the seven were 
identified as being muscle-invasive.  However, the numbers are too small to 
draw any conclusions from this, and a separate study would be warranted to 
assess effectiveness of identifying muscle-invasive patients at flexible 
cystoscopy.  Nevertheless, we do know that there has been a universal reduction
in delays, and so outcomes are likely to have improved regardless.
The majority of patients with muscle-invasive bladder cancer at RCHT Treliske 
are referred to Derriford Hospital in Plymouth for their definitive treatment, as 
cystectomy is not currently offered in Cornwall.  Therefore, we next intend to 
explore whether there are delays in the system once patients have been referred
to Derriford, and identify whether a similar simulation modelling approach could 
be used to reduce any bottlenecks in this part of the system, in order to further 
reduce to the time from referral to treatment for muscle-invasive bladder cancer 
patients.
Conclusions
Simulation modelling methods offer an effective means of identifying bottlenecks
in a system and predicting the impact of various efforts to reduce such 
bottlenecks.  The model in this project was used to facilitate discussion about 
delays in the system, and the evidence from the model was the primary 
motivation for effecting rapid and cost-neutral change in the system that has led 
to significant improvements for patients.  
In these times of increasing financial pressures, cost-neutral changes that 
improve patient outcomes and potentially save on treatment resources by 
avoiding more complex outcomes will be vital in ensuring sustainable services.  
We would strongly encourage others to explore simulation methods to assess 
how their own bladder cancer pathways might be improved, and urge NHS 
clinicians and decision-makers alike to increase their engagement with 
operational research more widely.
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